Double maintains 3 strategies that include PTGX - Protagonist Therapeutics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ETR | -<0.01% | $35.39B | +53.04% | 4.26% |
LYG | -<0.01% | $62.11B | +50.36% | 3.99% |
SONO | 0.01% | $1.21B | -36.80% | 0.00% |
LRCX | 0.02% | $116.34B | -12.35% | 5.21% |
PVH | 0.05% | $3.16B | -43.21% | 0.23% |
ABM | -0.05% | $2.89B | -9.50% | 2.10% |
BSBR | -0.05% | $20.43B | +9.66% | 5.23% |
CMP | 0.06% | $803.28M | +57.55% | 0.00% |
BR | 0.06% | $28.33B | +22.45% | 1.44% |
UONEK | 0.06% | $28.54M | -61.18% | 0.00% |
SAVA | 0.07% | $100.96M | -89.04% | 0.00% |
AG | 0.08% | $4.04B | +34.73% | 0.23% |
EW | 0.09% | $44.27B | -14.01% | 0.00% |
FTAI | 0.09% | $12.34B | +37.81% | 0.98% |
AIFU | 0.10% | $3.36B | 0.00% | 0.00% |
ODD | -0.10% | $3.19B | +70.26% | 0.00% |
MSTR | 0.10% | $105.84B | +141.39% | 0.00% |
APD | -0.11% | $62.80B | -0.30% | 2.51% |
CRDO | -0.11% | $12.16B | +146.35% | 0.00% |
TAL | 0.12% | $4.91B | +0.28% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RDFN | 58.70% | $1.38B | +63.47% | 0.00% |
MLYS | 56.13% | $1.01B | +23.41% | 0.00% |
KRYS | 31.08% | $4.03B | -23.27% | 0.00% |
MWA | 30.62% | $3.78B | +34.41% | 1.11% |
CRNX | 30.45% | $3.03B | -32.34% | 0.00% |
REGN | 28.35% | $55.99B | -49.54% | 0.17% |
ACLX | 28.31% | $3.65B | +20.18% | 0.00% |
XNCR | 28.27% | $677.55M | -56.77% | 0.00% |
KYMR | 27.67% | $3.15B | +39.86% | 0.00% |
APGE | 27.47% | $2.53B | -4.22% | 0.00% |
REPL | 27.39% | $753.91M | +10.88% | 0.00% |
COGT | 27.27% | $826.59M | -19.69% | 0.00% |
KLG | 27.24% | $1.34B | -13.61% | 4.13% |
TTC | 27.16% | $6.98B | -25.46% | 2.12% |
WSC | 27.14% | $5.15B | -26.75% | 0.50% |
ALKS | 26.39% | $5.14B | +25.60% | 0.00% |
DCO | 26.00% | $1.11B | +27.53% | 0.00% |
MFIN | 25.71% | - | - | 4.66% |
IOVA | 25.65% | $748.01M | -73.74% | 0.00% |
CNR | 25.15% | $3.76B | -27.75% | 0.99% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NPWR | -22.58% | $202.87M | -74.51% | 0.00% |
STG | -18.94% | $32.24M | -0.16% | 0.00% |
FRPT | -15.40% | $3.75B | -39.26% | 0.00% |
RKT | -14.70% | $2.07B | -2.84% | 0.00% |
RDDT | -13.76% | $21.23B | +74.47% | 0.00% |
MEOH | -12.16% | $2.36B | -31.18% | 2.11% |
LFWD | -11.80% | $13.21M | -74.25% | 0.00% |
SE | -10.78% | $84.40B | +109.04% | 0.00% |
FRO | -10.53% | $4.00B | -32.15% | 9.69% |
DHT | -10.29% | $1.83B | -2.98% | 6.93% |
PRMB | -9.74% | $10.86B | +30.17% | 1.32% |
BTCT | -9.61% | $21.81M | +56.22% | 0.00% |
TRMD | -9.32% | $1.70B | -51.08% | 22.20% |
NEXA | -9.25% | $650.28M | -37.13% | 0.00% |
VICR | -9.20% | $2.05B | +30.10% | 0.00% |
VSCO | -9.06% | $1.68B | +17.25% | 0.00% |
TNK | -8.88% | $1.55B | -33.79% | 2.18% |
IBKR | -8.56% | $22.28B | +68.03% | 0.53% |
VLRS | -8.49% | $535.92M | -32.95% | 0.00% |
BEKE | -8.34% | $21.81B | +19.16% | 1.90% |
Current Value
$55.161 Year Return
Current Value
$55.161 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -12.71% | $153.01M | 0.85% |
JMST | -9.11% | $3.84B | 0.18% |
XHLF | -8.77% | $1.64B | 0.03% |
DBMF | -8.51% | $1.19B | 0.85% |
STOT | -7.88% | $235.94M | 0.45% |
IBDQ | -7.71% | $3.04B | 0.1% |
BILS | -7.20% | $3.93B | 0.1356% |
FXC | -6.21% | $89.30M | 0.4% |
CLIP | -5.70% | $1.50B | 0.07% |
TAIL | -5.19% | $107.77M | 0.59% |
UDN | -4.53% | $145.23M | 0.78% |
HIGH | -4.34% | $182.34M | 0.52% |
FLMI | -4.33% | $694.47M | 0.3% |
QFLR | -4.26% | $297.68M | 0.89% |
BTAL | -3.91% | $298.87M | 1.43% |
HYDR | -3.90% | $31.71M | 0.5% |
FXE | -3.83% | $547.46M | 0.4% |
USL | -3.78% | $40.41M | 0.85% |
PTBD | -3.55% | $154.80M | 0.6% |
SHYD | -3.48% | $322.63M | 0.35% |
Yahoo
For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening their blood and increasing the risk for clots, heart attacks or strokes. The main treatment consists of regular blood draws—essentially bloodletting—to keep the disease in check.
SeekingAlpha
ASCO 2025: Profiling The Biggest Presentations At The Biggest Cancer Meeting
Yahoo
The United States market has shown a positive trend, climbing 1.4% in the last week and rising 12% over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on these favorable market conditions.
Finnhub
Presentation Operator MessageOperator Welcome to the Protagonist Therapeutics June 2 Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Monday, June 2, 2025.
Finnhub
Protagonist Therapeutics, Inc. and Takeda announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera , which met...
Yahoo
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PBE | 35.05% | $229.19M | 0.58% |
XBI | 31.73% | $4.89B | 0.35% |
IBB | 28.97% | $5.23B | 0.45% |
PTH | 25.76% | $104.10M | 0.6% |
BBH | 25.41% | $334.99M | 0.35% |
XPH | 24.37% | $153.36M | 0.35% |
DHS | 22.98% | $1.21B | 0.38% |
IHE | 22.01% | $568.11M | 0.39% |
PEY | 21.55% | $1.11B | 0.53% |
FDL | 21.49% | $5.46B | 0.43% |
FBT | 21.40% | $1.05B | 0.54% |
PINK | 21.37% | $131.18M | 0.5% |
SPYD | 21.33% | $6.84B | 0.07% |
FHLC | 21.19% | $2.45B | 0.084% |
CDC | 21.09% | $727.50M | 0.42% |
SCHD | 20.97% | $69.32B | 0.06% |
HDV | 20.86% | $10.94B | 0.08% |
VHT | 20.67% | $15.31B | 0.09% |
SPHD | 20.52% | $3.17B | 0.3% |
RSPH | 20.28% | $744.13M | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UGA | 0.02% | $72.57M | 0.97% |
ARKF | -0.04% | $1.08B | 0.75% |
FLMX | 0.05% | $46.53M | 0.19% |
MLN | -0.05% | $523.40M | 0.24% |
URNM | 0.05% | $1.61B | 0.75% |
EETH | 0.09% | $53.74M | 0.95% |
SOYB | 0.13% | $25.66M | 0.22% |
IMOM | 0.16% | $100.67M | 0.39% |
MNA | -0.17% | $234.66M | 0.77% |
IGOV | -0.18% | $1.12B | 0.35% |
ETHV | -0.18% | $121.08M | 0% |
CMBS | -0.20% | $438.36M | 0.25% |
MCHI | 0.22% | $6.45B | 0.59% |
DEFI | 0.23% | $13.54M | 0.94% |
GSG | 0.23% | $923.28M | 0.75% |
ETH | -0.29% | $1.27B | 0% |
DBC | -0.30% | $1.19B | 0.87% |
PZA | 0.30% | $2.81B | 0.28% |
ETHW | -0.33% | $250.40M | 0% |
IAPR | 0.33% | $249.49M | 0.85% |